Table 4: The comparison of clinical courses and management between the subgroups.

Total (n = 103) E group (n = 15) Other group (n = 88) P Use of inotropics, n (%) 28 (27) 2 (13) 26 (30) 0.192 Use of IABP, n (%) 12 (12) 0 (0) 12 (14) 0.128 Use of ACEI or ARB, n (%) 57 (55) 10 (67) 47 (53) 0.340 Use of beta blocker, n (%) 21 (20) 4 (27) 17 (19) 0.514 Use of diuretic, n (%) 40 (39) 2 (13) 38 (43) 0.028* Temporal pacemaker, n (%) 10 (10) 0 (0) 10 (11) 0.169 Cardioversion, n (%) 6 (6) 0 (0) 6 (7) 0.297 ICU hospitalization, n (%) 63 (61) 5 (33) 58 (66) 0.017* ICU hospitalization (days)† 2.0 (0–5.0) 1.0 (0–2.0) 3.0 (0–6.5) 0.005* Hospitalization (days)† 14.0 (7.0–28.0) 3.0 (3.0–9.0) 17.0 (8.0–32.0) 0.001* In-hospital cardiac mortality, n (%) 0 (0) 0 (0) 0 (0) — Cardiac mortality during followup, n (%) 0 (0) 0 (0) 0 (0) — Mortality during followup, n (%) 14 (14) 0 (0) 14 (16) 0.097 Recurrence, n (%) 0 (0) 0 (0) 0 (0) —

IABP: intra-aortic balloon pump; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; ICU: intensive care unit. †Presented as median (inter-quartile range). *Significant finding.